ncRNA basic information ncRNA ID: MIMAT0000098 ncRNA Database: miRBase ncRNA Name: miR-100-5p ncRNA Type: miRNA ncRNA Expression: down-regulated ncRNA Method: qRT-PCR ncRNA Target Gene: mTOR ncRNA Pathway: NA Evidence (ncRNA-drug): validated

drug basic information Drug ID: DB00515 (APRD00359) Drug Name: Cisplatin Drug Method: A549 resistance to DDP (A549/DDP) was established. Microarray was used to analyze microRNA (miRNA) expression profiles of A549 cells, A549/DDP cells, A549 exosomes, and A549/DDP exosomes. There was a strong correlation of miRNA profiles between exosomes and their maternal cells. A total of 11 miRNAs were significantly upregulated both in A549/DDP cells compared with A549 cells and in exosomes derived from A549/DDP cells in contrast to exosomes from A549 cells. A total of 31 downregulated miRNAs were also observed. miR-100-5p was the most prominent decreased miRNA in DDP-resistant exosomes compared with the corresponding sensitive ones. Downregulated miR-100-5p was proved to be involved in DDP resistance in A549 cells, and mammalian target of rapamycin (mTOR) expression was reverse regulated by miR-100-5p. Exosomes confer recipient cells resistance to DDP in an exosomal miR-100-5p-dependent manner with mTOR as its potential target both in vitro and in vivo. Exosomes from DDP-resistant lung cancer cells A549 can alter other lung cancer cells sensitivity to DDP in exosomal miR-100-5p-dependent manner. Drug Response: resistant

Cancer basic information Cancer: lung cancer Tissue/Cell: cell line (A549,A549/DDP)

Other information Title: Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner. Journal: Int J Nanomedicine Published: 2017 PubMed ID: 28553110